HIV Specialist masthead
APhA banner

Summer 2025

Volume 17, Number 2

Fallout from Federal Cuts

Features

Featured Article

“Community is an Act of Resistance”

AAHIVM Advocacy Town Hall

By Adrianne Wyatt, MA, HIV Specialist staff writer

Fear, uncertainty, stress, and anger. Disruptions to care and research. Funding terminations. These are just some of the things many…
At a Crossroads

At a Crossroads: Why HIV Specialists Must Embrace Advocacy and Speak Out

By Gary F. Spinner, DMSc, MPH, PA, AAHIVS

Since the earliest days of the HIV epidemic, advances in HIV medicine have profoundly transformed the health care system itself,…
Unraveling the Safety Net

Unraveling the Safety Net

How Federal Changes are Stripping Away Hope for People with HIV

By Guerline Verger-Coreus MBA, MSN, RN, RAC-CT, and Elizabeth Sherman, PharmD

Recent upheavals within the federal government and public health infrastructure are already casting a shadow over the lives of our…
We Need To Keep Fighting

‘We Need To Keep Fighting’: HIV Activists Organize To Save Lives as Trump Guts Funding

By Amy Maxmen

Cedric Sturdevant woke up with “a bit of depression” but made it to church, as he does every Sunday. In…
Donald STOP 02

Donald, STOP!

Trump Wages War Against HIV and DEI

By Brian J. Downs, D.O., MBA, AAHIVS

President Donald Trump has a stated mission to “drain the swamp” or, in other words, to rid our society of…

Sections

LFTD Bruce Packet
Letter from the Director

Standing Together Against Health Policy Headwinds

By Bruce J. Packett II Executive Director, AAHIVM
In the News

The American Academy of HIV Medicine Announces 2025 Dr. Dawn K. Smith HIV Prevention Clinical Fellowship Class
In the News

American Academy of HIV Medicine Statement on the Cuts to the Department of Health and Human Services

Eliminating Essential Public Health Services Harms All Americans
In the News

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering Six Months of Protection

Approval Based on Phase 3 PURPOSE 1 and PURPOSE 2 Data that Showed ≥99.9 percent of Participants Remained HIV Negative on Twice-Yearly Injectable Yeztugo

In the News

Two HIV Vaccine Trials Show Proof of Concept for Pathway to Broadly Neutralizing Antibodies

North American and African clinical trials led by Scripps Research, IAVI, and additional collaborators across the U.S. and Africa mark progress toward an effective HIV vaccine.
At the Forefront

Student Perspectives: Identifying Barriers and Support Needed for Entering the HIV Care Workforce

By Deja Robinson, AAHIVM Education Program Manager
Clinical Research Update

Clinical Research Update – Summer 2025
Membership banner
Scroll to Top

Search